www.celljournal.org

Supplementary Information for

Evaluation of Placental Alkaline Phosphatase Expression as A Potential Target of Solid Tumors Immunotherapy by Using Gene and Protein Expression Repositories

Mohsen Basiri, Ph.D.[1]*, Saghar Pahlavanneshan, Ph.D.[2]

1.Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
2. Medical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Corresponding Address: P.O.Box: 16635-148, Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
Email: basiri@royaninstitute.org



Fig.S1: Expression of two known immunotherapy targets across solid tumors. The top and bottom panel shows, respectively, the expression of *MSLN* (Mesothelin) and ERBB2 (HER-2) in the cancers with more than 2-fold increased expression of these genes. *; P<0.01, BRCA; Breast invasive carcinoma, CESC; Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD; Clone adenocarcinoma, DLBC; Lymphoid neoplasm diffuse large B-cell lymphoma, GBM; Glioblastoma multiforme, KIRP; Kidney renal papillary cell carcinoma, LUAD; Lung adenocarcinoma, OV; Ovarian cancer, PAAD; Pancreatic adenocarcinoma, READ; Rectum adenocarcinoma, STAD; Stomach adenocarcinoma, THYM; Thymoma, TPM; Transcript per million, and UCEC; Uterine corpus endometrial carcinoma.